About Fractyl
Fractyl is a publicly listed company based in Lexington (United States) founded in 2010. Endoscopic procedures for type-2 diabetes treatment are developed. Fractyl has raised $345.27 million across 7 funding rounds from investors including Bessemer Venture Partners, Maverick Ventures and M28 Capital. The company has 107 employees. Its website fractyl.com draws about 16 thousand monthly visits. Fractyl offers products and services including Revita and Rejuva. Its focus areas include Life Sciences, Diabetes, Medical Devices and Therapeutic Devices. Its legal entity is Fractyl Health, Inc. Its competitors include BioAge Labs, Carmot and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
Fractyl was founded in 2010 and is headquartered in Lexington, United States. Operations focus on the medical device sector, where an investigational trans-oral procedure called Revita duodenal mucosal resurfacing (DMR) is developed to address type-2 diabetes. The procedure, performed via the proprietary Revita System, involves hydrothermal ablation of the duodenal lining to influence glucose control and insulin resistance. A console and single-use balloon catheter are utilized in the process.
- Headquarters Lexington, United States
- Employees 107
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website fractyl.com
- Social LinkedIn X Facebook
- Legal Name Fractyl Health, Inc.
- Net Profit-$140.95 M (USD)-105.19as on Dec 31, 2025
- EBITDA-$95.69 M (USD)-3.05as on Dec 31, 2025
- Total Equity Funding$345.27M (USD)
in 7 rounds
- Latest Funding Round$100M (USD), Series F
Jun 2021
- InvestorsBessemer Venture Partners
& 17 more
- Employee Count107
Products & Services of Fractyl
Fractyl offers a comprehensive portfolio of products and services, including Revita and Rejuva.
Outpatient procedure to resurface duodenum for obesity root cause treatment
Platform for long-term remission of obesity and type 2 diabetes
Funding Insights of Fractyl
Fractyl has successfully raised a total of $345.27M across 7 strategic funding rounds. The most recent funding activity was a Series F round of $100 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $345.27M
- Total Rounds 7
- Last Round Series F — $100M
- First Round $14.35M
(Mar 2013)
- Investors Count 18
All 7 funding rounds of Fractyl with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $100M | Series F | – | Maverick Ventures, M28 Capital | – |
| Aug 2020 | $55M | Series E | – | Taiwania Capital | |
| Mar 2020 | $44.75M | Series D | – | – | – |
| Nov 2017 | $44M | Series D | – | – | |
| Feb 2016 | $47.17M | Series C | – | Deerfield Triarc Capital | |
| Sep 2014 | $40M | Series C | – | Mithril | |
| Mar 2013 | $14.35M | Series B | – | – | – |
18 investors in total: 18 institutional.
Investors in Fractyl
Fractyl has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Bessemer Venture Partners, Maverick Ventures and M28 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech and life-sciences firms are funded across the US. | maverickventures.com | San Francisco, United States | ||
A firm focused on biotechnology investments for prevalent diseases is operated. | populationhp.com | |||
VC firm focusing on technology companies | taiwaniacapital.com | Taipei, Taiwan | ||
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Investment and transformation services for entrepreneurs in technology and finance sectors. | generalcatalyst.com | |||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Private equity investments are made in the UK and US. | mithril.com | Austin, United States | ||
Venture capital firm supporting AI founders through investments and community. | trueventures.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Funding and expertise are provided for medical device development. | 2017 | emvllp.com | San Jose, United States |
Investor details for Fractyl
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Fractyl
48 people are tracked at Fractyl (22 in leadership, 6 in board & advisors, 20 in team); the tracked headcount is 107.
| Name | Role | Group |
|---|---|---|
Carley Balbuena | Associate Director Human Resources | Leadership |
Harith Rajagopalan | Co-Founder & CEO | Leadership |
Lelia Adelina Paunescu | Head Of Clinical Operations | Leadership |
Jay Caplan | Co-Founder & President | Leadership |
Pim Grondstra | Sr. Director, Supply Chain & Logistics | Leadership |
Alice Liou Fitzpatrick | Director, Gene Therapy | Leadership |
Brian Luque | Executive Director, Head Of Investor Relations And Corporate Development | Leadership |
Jon Fitzgerald | VP of Quality Assurance & Regulatory Affairs | Leadership |
Timothy Kieffer | Chief Scientific Officer | Leadership |
Emily Sorrentine | Market Adoption & Engagement Leader/associate Director Procedural Training & Execution | Leadership |
Emily Cozzi | Executive Director, Scientific And Medical Affairs | Leadership |
Jeremy Trelstad | Executive Director Human Resources | Leadership |
Hui Zhang | Director Of Biostatistics | Leadership |
Maureen Shanahan | Director, Medical Science Liaisons | Leadership |
Shimyn Slomovic | Executive Director | Head Of Gene Therapy R&d | Leadership |
Lin Quek | Associate Director, Gene Therapy Research | Leadership |
Maureen Cormier | Associate Director, Medical Science Liaison | Leadership |
Lisa Davidson | Chief Financial Officer | Leadership |
Len Rosberg | VP of Manufacturing | Leadership |
Kelly Barnes | Director | Leadership |
28 more people are available in the full profile.
Complete people profiles for Fractyl
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Fractyl
Fractyl is a publicly listed company on the NASDAQ with ticker symbol GUTS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Feb 2024
- Listed onNASDAQ: GUTS
- Listed entityFractyl Health, Inc.
- Exchange sectorHealth technology
Timeline of Fractyl
4 dated milestones of Fractyl across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Fractyl is founded.
- Funding First funding round of $14.3M.
- Funding Latest funding round, Series F, of $100.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Fractyl
Fractyl has 3 listed competitors in our database, 3 of them funded. They include BioAge Labs, Carmot and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. | ||
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of Fractyl
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fractyl
The website of Fractyl (fractyl.com) receives about 16.2K visits a month.
- Monthly visits16.2K
▼ 9.8% vs previous month
Websites whose visitors overlap most with Fractyl. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| acutusmedical.com | 100% | View details | |||
| icumed.com | 100% | 119.1K | #303,854 | View details |
Top companies in Diabetes
3 companies that operate in the same segment as Fractyl (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fractyl
Complete news archive for Fractyl
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fractyl
Fractyl was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Fractyl is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Fractyl is a funded company, having raised a total of $345.27M across 7 funding rounds to date. The company's 1st funding round was a Series B of $14.35M, raised on Mar 2013.
Fractyl has 107 employees.
Fractyl was founded in 2010 and is headquartered in Lexington, United States. Operations focus on the medical device sector, where an investigational trans-oral procedure called Revita duodenal mucosal resurfacing (DMR) is developed to address type-2 diabetes. The procedure, performed via the proprietary Revita System, involves hydrothermal ablation of the duodenal lining to influence glucose control and insulin resistance. A console and single-use balloon catheter are utilized in the process.
Fractyl's top competitors include BioAge Labs, Carmot and Altimmune.
Fractyl offers Revita and Rejuva.
Yes, Fractyl is publicly traded on NASDAQ under the ticker symbol GUTS.
Fractyl has 18 investors. Key investors include Bessemer Venture Partners, Maverick Ventures, M28 Capital, Population Health Partners, and Taiwania Capital.
Fractyl operates through Fractyl Health, Inc..